Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer

Merle I Ronden,Idris Bahce,Sayed M S Hashemi,Chris Dickhoff,Patricia F de Haan,Annemarie Becker,Femke O B Spoelstra,Max R Dahele,Rania Ali,Marian A Tiemessen,Svitlana Tarasevych,Karen Maassen van den Brink,Cornelis J A Haasbeek,Johannes M A Daniels,Marjolein van Laren,Wilko F A R Verbakel,Suresh Senan

Lung Cancer（2021）

引用 9|浏览64

暂无评分

摘要

•MDT decision-making for stage III NSCLC was studied between 2015–2017.•Surgery or chemo-radiotherapy were recommended in just 61 % of patients.•Deaths from NSCLC at ≤2 years were seen in 41–43 % after all treatments.•Better tolerated and more effective treatments are needed in stage III NSCLC.

查看译文

关键词

Non-small cell lung cancer,Stage III,Multidisciplinary tumor board,Predictors patterns of care,Treatment outcome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要